Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia

scientific article published in October 1994

Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode1994PNAS...9110722Z
P356DOI10.1073/PNAS.91.22.10722
P932PMC publication ID45094
P698PubMed publication ID7938018
P5875ResearchGate publication ID15261255

P2093author name stringCohen O
Wetzler M
Ben-Yehuda D
Avraham A
Ben-Neriah Y
Melloul D
Zion M
P2860cites workThe first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemiaQ24613429
Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemiaQ28265670
Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused geneQ28287743
Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogeneQ28512170
Role for DNA methylation in genomic imprintingQ29618669
Hypomethylation distinguishes genes of some human cancers from their normal counterpartsQ29619217
Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survivalQ33457480
N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-ablQ33559187
Transforming genes in chronic myelogenous leukemiaQ33560907
Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemiaQ34302000
Use of restriction enzymes to detect potential gene sequences in mammalian DNA.Q35079757
Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemiaQ35595317
Differential expression of type-specific c-abl mRNAs in mouse tissues and cell linesQ36847864
Rearrangement and amplification of c-abl sequences in the human chronic myelogenous leukemia cell line K-562Q37344872
Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemiaQ37511866
Recurring chromosome abnormalities in leukemia and lymphomaQ37929357
High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines.Q38339731
Therapeutic options in chronic myeloid leukaemiaQ38617810
Allele-specific hypermethylation of the retinoblastoma tumor-suppressor geneQ40562591
DNA methylation and genomic imprintingQ40754526
The nuclear tyrosine kinase c-Abl negatively regulates cell growthQ42799874
Parental origin of chromosomes involved in the translocation t(9;22).Q43592920
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid geneQ43900370
Maternal-specific methylation of the imprinted mouse Igf2r locus identifies the expressed locus as carrying the imprinting signal.Q48125063
Alternative 5' exons in c-abl mRNA.Q48368062
Activation and somatic mutation of the translocated c-myc gene in burkitt lymphoma cellsQ48393003
Variables influencing the timing of marrow transplantation in patients with chronic myelogenous leukemia.Q51658122
Fused transcript of abl and bcr genes in chronic myelogenous leukaemiaQ59064021
Imprints on islandsQ64441632
Long-range mapping of the Philadelphia chromosome by pulsed-field gel electrophoresis.Q64974705
Studies of BCR and ABL gene rearrangements in chronic myelogenous leukemia patients by conventional and pulsed-field gel electrophoresis using gel insertsQ69540304
Methylation of the Hprt gene on the inactive X occurs after chromosome inactivationQ69687603
Alternative 5' end of the bcr-abl transcript in chronic myelogenous leukemiaQ69944833
Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemiaQ70167698
Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populationsQ70220517
Lack of imprinting of BCRQ72017447
Methylation of the major breakpoint cluster region (M-bcr) in Philadelphia-positive CMLQ72078669
P433issue22
P407language of work or nameEnglishQ1860
P921main subjectleukemiaQ29496
DNA methylationQ874745
P304page(s)10722-10726
P577publication date1994-10-01
P1433published inProceedings of the National Academy of Sciences of the United States of AmericaQ1146531
P1476titleProgressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia
P478volume91

Reverse relations

cites work (P2860)
Q73916772ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL
Q33961765Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia
Q36573030Aberrant silencing of the CpG island-containing human O6-methylguanine DNA methyltransferase gene is associated with the loss of nucleosome-like positioning
Q35058707Advanced-phase chronic myeloid leukemia
Q41167757Are ABL and BCR imprinted?
Q35184329Chronic myelogenous leukemia: a review and update of therapeutic strategies
Q34765301Chronic myelogenous leukemia: mechanisms underlying disease progression.
Q38193659Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy
Q38344869Control of methylation spreading in synthetic DNA sequences by the murine DNA methyltransferase
Q41730013DNA methylation as a target for drug design
Q34792998DNA methylation changes in leukaemia
Q37873228DNA methylation in cancer development, diagnosis and therapy--multiple opportunities for genotoxic agents to act as methylome disruptors or remediators.
Q36986433DNA methylation: its role in cancer development and therapy
Q41592450DNA methylation: regulation of gene expression and role in the immune system
Q41723122DNA methylator and mismatch repair phenotypes are not mutually exclusive in colorectal cancer cell lines
Q38941081DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia
Q33806626Differential methylation of genes associated with cell adhesion in preeclamptic placentas.
Q24810666Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region
Q36429559Epigenetic therapy with decitabine for myelodysplasia and leukemia
Q42816880Heritable gene repression through the action of a directed DNA methyltransferase at a chromosomal locus
Q33536277High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene
Q43658865Identification of DNA methylation differences during tumorigenesis by methylation-sensitive arbitrarily primed polymerase chain reaction
Q40305071Identification of novel Runx1 (AML1) translocation partner genes SH3D19, YTHDf2, and ZNF687 in acute myeloid leukemia
Q35828742Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia
Q39520549Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele
Q36142412Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients.
Q35571293Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Q80586970Loss of c-abl facilitates anchorage-independent growth of p53- and RB- deficient primary mouse embryonic fibroblasts
Q34278271Malignancy: Tumor Suppressor Gene Aberrations in Acute Myelogenous Leukemia
Q39808706Methylation of CpG dinucleotides in the open reading frame of a testicular germ cell-specific intronless gene, Tact1/Actl7b, represses its expression in somatic cells
Q54266084Methylation status of CEBPA gene promoter in chronic myeloid leukemia.
Q38289376Methylation-associated Transcriptional Silencing of the Major Histocompatibility Complex-linked hsp70 Genes in Mouse Cell Lines
Q34176567NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia
Q36851400Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases
Q35728742Novel therapies for patients with chronic myeloid leukemia
Q54839818Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.
Q73934848Possible prediction of myeloid and lymphoid crises in chronic myelocytic leukemia at onset by determining the methylation status of the major breakpoint cluster region
Q35571288Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg
Q38327560RETRACTED: Alteration of p73 in acute myelogenous leukemia
Q33959680Roles of cell division and gene transcription in the methylation of CpG islands.
Q34053843Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas
Q33543982The DNA methylation paradox
Q36822880Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).
Q41607022p53 mutations, methylation and genomic instability in the progression of chronic myeloid leukaemia